Q1 2025 BridgeBio Pharma Inc Earnings Call Transcript
Key Points
- BridgeBio Pharma Inc (BBIO) reported strong revenue of $36.7 million from the launch of Attruby, indicating positive market reception.
- Attruby demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, with a 50% reduction in cardiovascular hospitalization.
- The company has a robust pipeline with three Phase III readouts expected in the next year, including efforts in chronic hypoparathyroidism.
- BridgeBio Pharma Inc (BBIO) has a strong financial position with $540.6 million in cash and cash equivalents, excluding anticipated regulatory milestone payments.
- The company is expanding its market presence with the rapid enrollment of trials and positive progress in key additional markets, such as hypochondroplasia.
- Operating expenses increased to $218.4 million in Q1 2025, reflecting continued investment in the Attruby brand and late-stage pipeline.
- SG&A expenses rose significantly to $106.4 million, driven by the commercial rollout of Attruby.
- The company faces competition in the ATTR-CM market, with new entrants potentially impacting market share.
- There is uncertainty regarding the long-term sustainability of current growth rates, particularly in the face of potential market saturation.
- The company acknowledges potential risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
Good afternoon. I will be your conference operator today. (Operator Instructions) Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law.
With that completed, BridgeBio, you may begin your conference.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
